• Log in with Facebook Log in with Twitter Log In with Google      Sign In    
  • Create Account
              Advocacy & Research for Unlimited Lifespans

Adverts help to support the work of this non-profit organisation. To go ad-free join as a Member.


Shift Bioscience


  • Please log in to reply
No replies to this topic
⌛⇒ current fundraiser: B.A.S.E Victor @ OpenCures

#1 caliban

  • Admin, Advisor, Director
  • 8,990 posts
  • 1,829
  • Location:UK

Posted 29 March 2019 - 08:18 PM


We have identified small molecule ‘Shift’ drugs that combat diverse age-accumulated mitochondrial genome damage


We will minimize costs and timescales for clinical development of Shift drugs by first targeting the orphan disease MELAS, which is caused by inherited mitochondrial dysfunction. A clinical trial for MELAS requires fewer participants due to the rarity of the disease and the larger degree of unmet clinical need. Drug efficacy is easier to demonstrate due to clearer biological/clinical endpoints.

0 user(s) are reading this topic

0 members, 0 guests, 0 anonymous users